Zatosetron (Vietnamese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Zatosetron" in Vietnamese language version.

refsWebsite

Global rank Vietnamese rank

6nih.gov

4^th place

7^th place

4doi.org

2^nd place

1archive.org

6^th place

4^th place

archive.org

Schwartz, SM; Goldberg, MJ; Gidda, JS; Cerimele, BJ (1994). “Effect of zatosetron on ipecac-induced emesis in dogs and healthy men”. Journal of Clinical Pharmacology. 34 (3): 250–4. doi:10.1002/j.1552-4604.1994.tb03994.x. PMID 7517409.

doi.org

Robertson, DW; Lacefield, WB; Bloomquist, W; Pfeifer, W; Simon, RL; Cohen, ML (1992). “Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships”. Journal of Medicinal Chemistry. 35 (2): 310–9. doi:10.1021/jm00080a016. PMID 1732548.
Schwartz, SM; Goldberg, MJ; Gidda, JS; Cerimele, BJ (1994). “Effect of zatosetron on ipecac-induced emesis in dogs and healthy men”. Journal of Clinical Pharmacology. 34 (3): 250–4. doi:10.1002/j.1552-4604.1994.tb03994.x. PMID 7517409.
Smith, WT; Londborg, PD; Blomgren, SL; Tollefson, GD; Sayler, ME (1999). “Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety”. Journal of Clinical Psychopharmacology. 19 (2): 125–31. doi:10.1097/00004714-199904000-00006. PMID 10211913.
Bendele, A; Means, J; Shoufler, J; Schmalz, C; Hanasono, G; Symanowski, J; Adams, E (1995). “Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys”. Drug and Chemical Toxicology. 18 (1): 61–82. doi:10.3109/01480549509017858. PMID 7768200.

nih.gov

pubmed.ncbi.nlm.nih.gov

Cohen, ML; Bloomquist, W; Gidda, JS; Lacefield, W (1990). “LY277359 maleate: a potent and selective 5-HT3 receptor antagonist without gastroprokinetic activity”. The Journal of Pharmacology and Experimental Therapeutics. 254 (1): 350–5. PMID 2366187.
Robertson, DW; Lacefield, WB; Bloomquist, W; Pfeifer, W; Simon, RL; Cohen, ML (1992). “Zatosetron, a potent, selective, and long-acting 5HT3 receptor antagonist: synthesis and structure-activity relationships”. Journal of Medicinal Chemistry. 35 (2): 310–9. doi:10.1021/jm00080a016. PMID 1732548.
Schwartz, SM; Goldberg, MJ; Gidda, JS; Cerimele, BJ (1994). “Effect of zatosetron on ipecac-induced emesis in dogs and healthy men”. Journal of Clinical Pharmacology. 34 (3): 250–4. doi:10.1002/j.1552-4604.1994.tb03994.x. PMID 7517409.
Smith, WT; Londborg, PD; Blomgren, SL; Tollefson, GD; Sayler, ME (1999). “Pilot study of zatosetron (LY277359) maleate, a 5-hydroxytryptamine-3 antagonist, in the treatment of anxiety”. Journal of Clinical Psychopharmacology. 19 (2): 125–31. doi:10.1097/00004714-199904000-00006. PMID 10211913.
Williams, PD; Calligaro, DO; Colbert, WE; Helton, DR; Shetler, T; Turk, JA; Jordan, WH (1991). “General pharmacology of a new potent 5-hydroxytryptamine antagonist”. Arzneimittel-Forschung. 41 (3): 189–95. PMID 1867653.
Bendele, A; Means, J; Shoufler, J; Schmalz, C; Hanasono, G; Symanowski, J; Adams, E (1995). “Chronic toxicity of zatosetron, a 5-HT3 receptor antagonist, in rhesus monkeys”. Drug and Chemical Toxicology. 18 (1): 61–82. doi:10.3109/01480549509017858. PMID 7768200.